The researchers found that women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator had a lower risk for ventricular tachyarrhythmias or death compared to men. HealthDay ...

Results from Optimizing Beta-Blocker Dosage in Female Patients Using the Wearable Cardioverter Defibrillator (OPT-BB Women) were presented at ESC-HF 2026 CHELMSFORD, Mass., May 12, 2026--(BUSINESS ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Just because implantable defibrillators have been found to prevent ...

SAN DIEGO, CA—The observational BIO-LIBRA study, which enrolled nearly 50% women, has revealed important outcome differences by both sex and device type among patients with nonischemic cardiomyopathy ...

Among patients with advanced HFrEF, women, compared with men, are less likely to receive an implantable cardiac defibrillator. Women who have advanced heart failure with reduced ejection fraction ...

Findings seen for ventricular arrhythmias or death at one year for patients with nonischemic cardiomyopathy. (HealthDay News) — There is a lower risk of one-year ventricular arrhythmias or death in ...

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that insights from the LifeVest® wearable cardioverter defibrillator (WCD) helped physicians ...